1. Home
  2. VSECU vs ANAB Comparison

VSECU vs ANAB Comparison

Compare VSECU & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VSE Corporation Tangible Equity Units

VSECU

VSE Corporation Tangible Equity Units

N/A

Current Price

$47.80

Market Cap

1.4B

Sector

N/A

ML Signal

N/A

ANAB

AnaptysBio Inc.

HOLD

Current Price

$52.81

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VSECU
ANAB
Founded
N/A
2005
Country
United States
United States
Employees
1600
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.3B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
VSECU
ANAB
Price
$47.80
$52.81
Analyst Decision
Buy
Analyst Count
0
12
Target Price
N/A
$71.67
AVG Volume (30 Days)
25.3K
520.1K
Earning Date
N/A
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
91.02
EPS
N/A
N/A
Revenue
N/A
$234,603,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$52.14
P/E Ratio
N/A
N/A
Revenue Growth
N/A
157.01
52 Week Low
$38.45
$17.11
52 Week High
$65.93
$73.30

Technical Indicators

Market Signals
Indicator
VSECU
ANAB
Relative Strength Index (RSI) 47.26 33.44
Support Level $44.42 $43.75
Resistance Level $58.80 $57.70
Average True Range (ATR) 3.18 3.56
MACD 0.30 -1.03
Stochastic Oscillator 26.36 6.38

Price Performance

Historical Comparison
VSECU
ANAB

About VSECU VSE Corporation Tangible Equity Units

VSE Corp is a diversified aftermarket products and services company serving commercial and government markets. The Company's operations include aircraft and airframe parts supply and distribution, and MRO services of aircraft components and engine accessories. The Company operates as a single reportable segment: Aviation, which is a provider of aftermarket parts distribution and MRO services for components and engine accessories supporting commercial, business, and general aviation operators.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: